Refractory Orofacial Pain: Is It the Patient or the Pain?

Aims: To highlight and discuss the term “refractory” when used to describe pain conditions and its application to orofacial pain, as well as to highlight the factors that must be considered in a refractory patient. Methods: A scoping review of recent publications (2010 to 2021) applying the term “refractory” to orofacial pain was conducted, and this paper presents their limitations and definitions. Results: The term “refractory” is often used to describe pain instead of “persistent” or “nonresponsive.” There are clear definitions in the use of refractory for migraine, cluster headaches, and other nonheadache disorders. Currently, the term is applied to pain conditions in order to alter the patient pathway of treatment, sometimes to escalate a patient from one care sector to another and sometimes to escalate treatment to more costly surgical interventional techniques. Conclusion: There is a need for a clear definition for use of the term “refractory” in orofacial pain conditions, excluding migraine and cluster headaches. In addition, there is a requirement for a consensus on the implications of the use of refractory when assessing and managing patients.

nonresponsive; orofacial; pain; persistent; refractory

1. Rodriguez E, Sakurai K, Xu J, et al. A craniofacial-specific monosynaptic circuit enables heightened affective pain. Nat Neurosci 2017;20:1734–1743.

2. Van der Cruyssen F, Politis C. Neurophysiological aspects of the trigeminal sensory system: An update. Rev Neurosci 2018;29:115–123.

3. May A, Svensson P. One nerve, three divisions, two professions and nearly no crosstalk? Cephalalgia 2017. Epub ahead of print Jan 1.

4. International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia 2020;40:129–221.

5. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, ed 3. Cephalalgia 2018;38:1–211.

6. Clark MR, Cox TS. Refractory chronic pain. Psychiatr Clin North Am 2002;25:71–88.

7. Brant JM, Keller L, McLeod K, Yeh C, Eaton LH. Chronic and refractory pain: A systematic review of pharmacologic managment in oncology . Clin J Oncol Nurs 2017;21(3 suppl):31–53.

8. Intractable Pain Treatment Act. Occupations Code ch 107, § 107.001 (2003). http://www.statutes.legis.state.tx.us/Docs/OC/htm/OC.107.htm. Accessed 20 October 2021.

9. What is persistent pain? The Pennine Acute Hospitals NHS Trust. https://www.pat.nhs.uk/what-is-persistent-pain.htm. Accessed 20 October 2021.

10. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain 2012;156:1003–1007.

11. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 1997;41:154–158.

12. Idiopathic. Concise Medical Dictionary, ed 8. Oxford Univeristy Press: 2010.

13. Deer TR, Caraway DL, Wallace MS. A definition of refractory pain to help determine suitability for device implantation. Neuromodulation 2014;17:711–715.

14. Baron R, Backonja MM, Eldridge P, et al. Refractory Chronic Pain Screening Tool (RCPST): A feasibility study to assess practicality and validity of identifying potential neurostimulation candidates. Pain Med 2014;15:281–291.

15. Gierthmühlen J, Baron R. Neuropathic Pain. Semin Neurol 2016;36:462–468.

16. Lipton RB, Silberstein S. Migraine headache: Diagnosis and current and emerging preventive treatments. Prim Care Companion CNS Disord 2018;20(suppl E1):li17059su1c.

17. Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine: Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). J Headache Pain 2020;21:76.

18. Schulman EA, Lake AE 3rd, Goadsby PJ, et al. Defining refractory migraine and refractory chronic migraine: Proposed criteria from the Refractory Headache Special Interest Section of the American Headache Society. Headache 2008;48:778–782.

19. Mitsikostas DD, Edvinsson L, Jensen RH, et al. Refractory chronic cluster headache: A consensus statement on clinical definition from the European Headache Federation. J Headache Pain 2014;15:79.

20. Lambru G, Stubberud A, Rantell K, Lagrata S, Tronvik E, Matharu MS. Medical treatment of SUNCT and SUNA: A prospective open-label study including single-arm meta-analysis. J Neurol Neurosurg Psychiatry 2020;92:233–241.

21. Bendtsen L, Zakrzewska JM, Abbott J, et al. European Academy of Neurology guideline on trigeminal neuralgia. Eur J Neurol 2019;26:831–849.

22. Tate R, Rubin LM, Krajewski KC. Treatment of refractory trigeminal neuralgia with intravenous phenytoin. Am J Health Syst Pharm 2011;68:2059–2061.

23. Zakrzewska JM, Chaudhry Z, Nurmikko TJ, Patton DW, Mullens LE. Lamotrigine (lamictal) in refractory trigeminal neuralgia:Results from a double-blind placebo controlled crossover trial. Pain 1997;73:223–230.

24. Sridharan K, Sivaramakrishnan G. Interventions for refractory trigeminal neuralgia: A Bayesian mixed treatment comparison network meta-analysis of randomised controlled clinical trials. Clin Drug Investig 2017;37:819–831.

25. Cruccu G, Truini A. Refractory trigeminal neuralgia. Nonsurgical treatment options. CNS Drugs 2013;27:91–96.

26. Mitsikostas DD, Ljubisavljevic S, Deligianni CI. Refractory burning mouth syndrome: Clinical and paraclinical evaluation, comorbiities [sic], treatment and outcome. J Headache Pain 2017;18:40.

27. Lum VWM, Poh J. Refractory temporomandibular joint dislocation—Reduction using the wrist pivot method. Clin Pract Cases Emerg Med 2017;1:380–383.

28. Renton T. Tooth-related pain or not? Headache 2020;60: 235–246.

29. Wei DY, Moreno-Ajona D, Renton T, Goadsby P. Trigeminal autonomic cephalalgias presenting in a multidisciplinary tertiary orofacial pain clinic. J Headache Pain 2019;20:69.

30. Lambru G, Elias LA, Yakkaphan P, Renton T. Migraine presenting as isolated facial pain: A prospective clinical analysis of 58 cases. Cephalalgia 2020;40:1250–1254.

31. Stuginski-Barbosa J, Murayama RA, Conti PCR, Speciali JG. Refractory facial pain attributed to auriculotemporal neuralgia. J Headache Pain 2012;13:415–417.

32. Edwards RR, Dworkin RH, Turk DC, et al. Patient phenotyping in clinical trials of chronic pain treatments: IMMPACT recommendations. Pain 2016;157:1851–1871.

33. Scher AI, Rizzoli PB, Loder EW. Medication overuse headache: An entrenched idea in need of scrutiny. Neurology 2017;89:1296–1304.

34. Chen PK, Wang SJ. Medication overuse and medication overuse headache: Risk factors, comorbidities, associated burdensand nonpharmacologic and pharmacologic treatment approaches. Curr Pain Headache Rep 2019;23:60.

35. González-Oria C, Belvís R, Cuadrado ML, et al. Document of revision and updating of medication overuse headache (MOH). Neurologia (Engl Ed) 2021;36:229–240.

36. Van Deun L, de Witte M, Goessens T, et al. Facial pain: A comprehensive review and proposal for a pragmatic diagnostic approach. Eur Neurol 2020;83:5–16.

37. Samulowitz A, Gremyr I, Eriksson E, Hensing G. “Brave men” and “emotional women”: A theory-guided literature review on gender bias in health care and gendered norms towards patients with chronic pain. Pain Res Manag 2018;2018:6358624.

38. Mills SEE, Nicolson KP, Smith BH. Chronic pain: A review of its epidemiology and associated factors in population-based studies. Br J Anaesth 2019;123:e273–e283.

39. Tanner JJ, Johnson AJ, Terry EL, et al. Resilience, pain, and the brain: Relationships differ by sociodemographics. J Neurosci Res 2021;99:1207–1235.

40. Nestler EJ, Waxman SG. Resilience to stress and resilience to pain: Lessons from molecular neurobiology and genetics. Trends Mol Med 2020;26:924–935.

41. Goubert L, Trompetter H. Towards a science and practice of resilience in the face of pain. Eur J Pain 2017;21:1301–1315.

42. Melek LN, Devine M, Renton T. The psychosocial impact of orofacial pain in trigeminal neuralgia patients: A systematic review. Int J Oral Maxillofac Surg 2018;47:869–878.

43. Smith JG, Elias LA, Yilmaz Z, et al. The psychological and affective burden of posttraumatic neuropathy following injuries to the trigeminal nerve. J Orofac Pain 2013;27:293–303.

44. Smith JG, Karamat A, Melek LN, Jayakumar S, Renton T. The differential impact of neuropathic, musculoskeletal and neurovascular orofacial pain on psychosocial function. J Oral Pathol Med 2020;49:538–546.

45. Innes SI. Psychosocial factors and their role in chronic pain: A brief review of development and current status. Chiropr Osteopat 2005;13:6.

46. Arango-Dávila CA, Rincón-Hoyos HG. Depressive disorder, anxiety disorder and chronic pain: Multiple mainfestations of a common clinical and pathophysiological core. Rev Colomb Psquiatr (Engl Ed) 2018;47:46–55.

47. Hooten WM. Chronic pain and mental health disorders: Shared neural mechanisms, epidemiology, and treatment. Mayo Clin Proc 2016;91:955–970.

48. Maixner W, Fillingim RB, Williams DA, Smith SB, Slade GD. Overlapping chronic pain conditions: Implications for diagnosis and classification. J Pain 2016;17(suppl 9):T93–T107.

49. Denk F, McMahon SB. Neurobiological basis for pain vulnerability: Why me? Pain 2017;158(suppl 1):s108–s114.

50. Mills SEE, Nicolson KP, Smith BH. Chronic pain: A review of its epidemiology and associated factors in population-based studies. Br J Anaesth 2019;123:e273–e283.

51. Nelson S, Simons LE, Logan D. The incidence of adverse childhood experiences (ACEs) and their association with pain-related and psychosocial impairment in youth with chronic pain. Clin J Pain 2018;34:402–408.

52. Sachs-Ericsson N, Kendall-Tackett K, Hernandez A. Childhood abuse, chronic pain, and depression in the National Comorbidity Survey. Child Abuse Negl 2007;31:531–547.

53. Ellsberg M, Jansen HA, Heise L, et al. Intimate partner violence and women’s physical and mental health in the WHO multicountry study on women’s health and domestic violence: An observational study. Lancet 2008;371:1165–1172.

54. Haack M, Simpson N, Sethna N, Kaur S, Mullington J. Sleep deficiency and chronic pain: Potential underlying mechanisms and clinical implications. Neuropsychopharmacology 2020;45:205–216.

55. Miettinen T, Mäntyselkä P, Hagelberg N, Mustola S, Kalso E, Lötsch J. Machine learning suggests sleep as a core factor in chronic pain. Pain 2021;162:109–123.

56. Herrero Babiloni A, De Koninck BP, Beetz G, De Beaumont L, Martel MO, Lavigne GJ. Sleep and pain: Recent insights, mechanisms, and future directions in the investigation of this relationship. J Neural Transm (Vienna) 2020;127:647–660.

57. Herrero Babiloni A, Beetz G, Tang NKY, et al. Towards the endotyping of the sleeppain interaction: A topical review on multitarget strategies based on phenotypic vulnerabilities and putative pathways. Pain 2021;162:1281–1288.

58. Vikelis M, Dermitzakis EV, Vlachos GS, et al. Open label prospective experience of supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 for episodic migraine prophylaxis. J Clin Med 2020;10:67.

59. Sesti F, Capozzolo T, Pietropolli A, Collalti M, Bollea MR, Piccione E. Dietary therapy: A new strategy for management of chronic pelvic pain. Nutr Res Rev 2011;24:31–38.

60. Hagen K, Byfuglien MG, Falzon L, Olsen SU, Smedslund G. Dietary interventions for rheumatoid arthritis. Cochrane Database Syst Rev 2009;(1):CD006400.

61. Shipton EE, Shipton EA. Vitamin D deficiency and pain: Clinical evidence of low levels of vitamin D and supplementation in chronic pain states. Pain Ther 2015;4:67–87.

62. Straube S, Derry S, Straube C, Moore RA. Vitamin D for the treatment of chronic painful conditions in adults. Cochrane Database Syst Rev 2015;2015:CD007771.

63. Clark J, Nijs J, Yeowell G, Goodwin PC. What are the predictors of altered central pain modulation in chronic musculoskeletal pain populations? A systematic review. Pain Physician 2017;20:487–500.

64. Hellman N, Sturycz CA, Lannon EW, et al. Conditioned pain modulation in sexual assault survivors. J Pain 2019;20: 1027–1039.

65. Chiriac AM, Demoly P. Multiple drug hypersensitivity syn-drome. Curr Opin Allergy Clin Immunol 2013;13:323–329.

66. Omer HMRB, Hodson J, Thomas SK, Coleman JJ. Multiple drug intolerance syndrome: A large-scale retrospective study. Drug Saf 2014;37:1037–1045.

67. Faasse K, Grey A, Horne R, Petrie KJ. High perceived sensitivity to medicines is associated with higher medical care utilisation, increased symptom reporting and greater information-seeking about medication. Pharmacoepidemiol Drug Saf 2015;24:592–599.

68. Behera SK, Das S, Chengappa KG, Xavier AS, Selvarajan S. Multiple drug intolerance syndrome: An underreported distinct clinical entity. Curr Clin Pharmacol 2019;14:84–90.

69. Horne R, Faasse K, Cooper V, et al. The perceived sensitivity to medicines (PSM) scale: An evaluation of validity and reliability. Br J Health Psychol 2013;18:18–30.

70. Guo R, Chen LH, Xing C, Liu T. Pain regulation by gut microbiota: Molecular mechanisms and therapeutic potential. Br J Anaesth 2019;123:637–654.

71. Dworsky-Fried Z, Kerr BJ, Taylor AMW. Microbes, microglia, and pain. Neurobiol Pain 2020;7:100045.

72. Lorduy KM, Liegey-Dougall A, Haggard R, Sanders CN, Gatchel RJ. The prevalence of comorbid symptoms of central sensitization syndrome among three different groups of temporomandibular disorder patients. Pain Pract 2013; 13:604–613.

73. Drummond PD. Photophobia and autonomic responses to facial pain in migraine. Brain 1997;120:1857–1864.

74. Mostoufi SM, Afari N, Ahumamda SM, Reis V, Wetherell JL. Health and distress predictors of heart rat variability in fibromyalgia and other forms of chronic pain. J Psychosom Res 2012;72:39–44.

75. Koszewicz M, Mendak M, Konopka T, Koziorowska-Gawron E, Budrewicz S. The characteristics of autonomic nervous system disorders in burning mouth syndrome and Parkinson disease. J Orofac Pain 2012;26:315–320.

76. Zorina-Lichtenwalter K, Meloto CB, Khoury S, Diatchenko L. Genetic predictors of human chronic pain conditions. Neuroscience 2016;338:36–62.

77. Knezevic NN, Tverdohleb T, Knezevic I, Candido KD. The role of genetic polymorphisms in chronic pain patients. Int J Mol Sci 2018;19:1707.

78. Calvo M, Davies AJ, Hébert HL, et al. The genetics of neuropathic pain from model organisms to clinical application. Neuron 2019;104:637–653.

79. Naujokaitis D, Asmoniene V, Kadusevicius E. Cytochrome P450 2C19 enzyme, Cytochrome P450 2C9 enzyme, and Cytochrome P450 2D6 enzyme allelic variants and its possible effect on drug metabolism: A retrospective study. Medicine (Baltimore) 2021;100:e24545.

80. van Nguyen D, Chu HC, Vidal C, et al. Genetic susceptibilities and prediction modeling of carbamazepine and allopurinol-in-duced severe cutaneous adverse reactions in Vietnamese. Pharmacogenomics 2021;22:1–12.

81. Geha P, Yang Y, Estacion M, et al. Pharmacotherapy for pain in a family with inherited erythromelalgia guided by genomic analysis and functional profiling. JAMA Neurol 2016;73:659–667.

82. Ledermann K, Hasler G, Jenewein J, Sprott H, Schnyder U, Martin-Soelch C. 5’UTR polymorphism in the serotonergic receptor HTR3A gene is differently associated with striatal Dopamine D2/D3 receptor availability in the right putamen in fibromyalgia patients and healthy controls—Preliminary evidence. Synapse 2020;74:e22147.